Arrhythmias & electrophysiology
Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation
Authors' conclusion
In patients with AF, plasma levels of angiopoietin-2 were independently associated with subsequent hospitalization for heart failure and provided incremental prognostic value to clinical risk factors and NT-proBNP.
Study context
- Population
- Patients with atrial fibrillation (AF)
- Participants
- 2,987 vs 13,079
- Exposure
- Plasma angiopoietin-2 levels
- Explorationn = 2,987
- Validationn = 13,079
- Outcome
- Association of angiopoietin-2 with clinical characteristics and outcomes (HF hospitalization)
Methodological detailsexploration and validation cohorts
- Exploration and validation cohorts
Main finding
As reported in the abstract
Subsequent hospitalization for HF (third vs first quartile of angiopoietin-2)
Exploration
0.79
95% CI 0.75–0.82
c-index
Validation
0.76
95% CI 0.74–0.78
c-index
Third quartile vs First quartileHazard ratio (95% CI)
Exploration cohort; adjusted for age, creatinine, clinical characteristics
1.74(1.26–2.41)
Validation cohort
1.58(1.37–1.82)
- Association persisted after also adjusting for NT-proBNP, both cohorts
- P ≤ 0.001
Observational data: associations, not effects.
Further findings
Ischaemic stroke, CV and all-cause death, major bleeding
- No statistically significant associations consistent across both cohorts (full models incl. NT-proBNP)
Baseline correlates of angiopoietin-2
- Independently associated with AF on baseline ECG, persistent/permanent AF, age, history of HF, female sex, smoking, BMI, renal dysfunction, DM and NT-proBNP in both cohorts
Original publication
Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation. Europace. Published 18 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →